文献速递骨质疏松与代谢性骨病

质子泵抑制剂与甲状旁腺功能亢进症的关联:骨折风险增加的潜在机制——一项大型观察性队列研究的结果

The association between proton pump inhibitors and hyperparathyroidism: a potential mechanism for increased fracture-results of a large observational cohort study.
PubMed 文献 · Osteoporos Int · 2023-08-02

该研究基于TUDA队列的4139名爱尔兰老年人横断面数据,分析质子泵抑制剂(PPI)使用与甲状旁腺功能亢进症的关系。在服用钙补充剂者中,PPI使用与甲状旁腺功能亢进症显著相关(OR 1.56,CI 1.08-2.23,p=0.018),而不服用钙补充剂者中未观察到该关联。结果与PPI减少钙吸收、升高甲状旁腺激素从而增加骨折风险的假说一致。

要点

  • 在服用钙补充剂的老年人中,PPI使用与甲状旁腺功能亢进症显著相关(OR 1.56,CI 1.08-2.23,p=0.018)。
  • 在不服用钙补充剂者中,未观察到PPI使用与甲状旁腺功能亢进症的关系。
  • PPI使用者较非使用者年龄更大(74.8 vs 72.9岁,p<0.001),甲状旁腺功能亢进症患病率更高(17.8 vs 11.0%,p<0.001)。

核心结论

  • 在服用钙补充剂的老年人中,PPI使用与甲状旁腺功能亢进症显著相关,结果与PPI减少钙吸收、升高PTH进而介导骨折风险增加的假说一致。
  • 在不服用钙补充剂者中未观察到PPI使用与甲状旁腺功能亢进症的关系,可能归因于较低的膳食钙摄入。
  • 作者认为这些结果强调了监测PPI使用的重要性,尤其是在有骨折风险的老年人中。

研究设计与样本

  • 研究为TUDA研究的大样本横断面队列,纳入爱尔兰老年人。
  • 排除eGFR<30 ml/min和血清钙>2.5 mmol/l者,以避免慢性肾病和原发性甲状旁腺功能亢进症所致的甲状旁腺功能亢进症。
  • 甲状旁腺功能亢进症定义为甲状旁腺激素(PTH)>65 pg/ml,采用多变量回归模型分析PPI使用与甲状旁腺功能亢进症的关系。

主要发现

  • 共4139名参与者符合纳入标准,其中37.8%(n=1563)正在服用PPI药物。
  • 服用钙补充剂者中PPI使用比例为41.4%,不服用钙补充剂者中为35.4%。
  • 与PPI非使用者相比,PPI使用者年龄更大(74.8 vs 72.9岁,p<0.001),甲状旁腺功能亢进症患病率更高(17.8 vs 11.0%,p<0.001)。
  • 在服用钙补充剂者中,调整年龄、性别、体重指数、血清维生素D、eGFR、计时起立-行走测试、乳制品摄入、用药和合并症后,PPI使用与甲状旁腺功能亢进症显著相关(OR 1.56,CI 1.08-2.23,p=0.018)。
  • 在不服用钙补充剂者中,未观察到PPI使用与甲状旁腺功能亢进症的关系。

关键数值与推荐

  • 甲状旁腺功能亢进症定义为PTH>65 pg/ml。
  • 在服用钙补充剂者中,PPI使用与甲状旁腺功能亢进症的OR为1.56(CI 1.08-2.23,p=0.018)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Proton pump inhibitors (PPIs) are associated with increased risk of osteoporotic fracture; however, the mechanism is unclear. PPI users taking calcium supplements were more likely to have hyperparathyroidism compared to non-users (OR 1.56, CI 1.08-2.23, p = 0.018). This highlights the importance of monitoring PPI use, especially in older adults. PURPOSE: Proton pump inhibitors (PPIs) are associated with increased risk of osteoporotic fracture. Hyperparathyroidism may be implicated, but few studies have considered this relationship. This study evaluated the relationship between PPI use and hyperparathyroidism in older adults. METHODS: Participants were from the TUDA study, a large cross-sectional cohort of older Irish adults. Participants with an estimated glomerular filtration rate (eGFR) < 30 ml/min and serum calcium > 2.5 mmol/l were excluded to avoid hyperparathyroidism due to chronic renal disease and primary hyperparathyroidism. Hyperparathyroidism was defined as a parathyroid hormone (PTH) > 65 pg/ml. Multivariate regression models were used to analyse the relationship between PPI use and hyperparathyroidism. RESULTS: A total of 4139 participants met the inclusion criteria, of whom 37.8% (n = 1563) were taking PPI medication. PPI use was identified in 41.4% of calcium supplement users and 35.4% of non-calcium supplement users. Overall, compared to non-users of PPIs, those taking PPIs were older (74.8 vs 72.9 years, p < 0.001) and had a higher prevalence of hyperparathyroidism (17.8 vs 11.0%, p < 0.001). In those taking calcium supplements (but not in non-users), PPI use was significantly associated with hyperparathyroidism (OR 1.56, CI 1.08-2.23, p = 0.018) after adjusting for age, sex, body mass index, serum vitamin D, eGFR, timed-up-and-go, dairy intake, medications, and comorbidities. DISCUSSION: The results are consistent with the hypothesis of PPIs reducing calcium absorption, leading to a rise in PTH which could mediate increased fracture risk. No relationship of PPI use with hyperparathyroidism was observed in non-users of calcium supplements, possibly owing to lower dietary calcium intake. These results highlight the importance of monitoring PPI use, especially in older adults at risk of fracture.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Fitzpatrick D, Lannon R, Laird E, et al. The association between proton pump inhibitors and hyperparathyroidism: a potential mechanism for increased fracture-results of a large observational cohort study. Osteoporos Int. 2023. PMID: 37530847. doi:10.1007/s00198-023-06867-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。